Argus Lifts Price Target for Johnson & Johnson to $355

Apr 22, 2026 21:26 UTC

JNJ

Medium term

Analyst firm Argus has reiterated its Buy rating on Johnson & Johnson, citing positive outlooks for 2026. The price target was increased from $340 to $355.

Price target raised to $355 from $340
Buy rating reiterated by Argus
Valuation set at 16x 2026 earnings estimates
Focus on sales growth and long-term guidance

Argus Research has updated its outlook on Johnson & Johnson (NYSE: JNJ), maintaining a Buy rating while increasing the stock's price target. The adjustment reflects a positive view of the company's sales growth trajectory and its guidance leading into 2026. As one of the most heavily weighted components of the S&P 500, JNJ's performance remains a key indicator for broader healthcare sector stability. The firm's ability to maintain growth across its pharmaceutical and medical technology segments continues to be a primary driver for institutional investors. The new price target of $355, up from the previous $340, is derived from a valuation multiple of 16 times the projected earnings for 2026. This suggests a steady growth expectation from the research firm. While analyst upgrades often provide short-term support for a stock's price, the long-term market impact will depend on the company's ability to execute its strategic goals and meet the earnings estimates used in this valuation.